Lipocalin-2 negatively regulates epithelial-mesenchymal transition through matrix metalloprotease-2 downregulation in gastric cancer.
Epithelial–mesenchymal transition
Gastric cancer
Lipocalin-2
Journal
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
ISSN: 1436-3305
Titre abrégé: Gastric Cancer
Pays: Japan
ID NLM: 100886238
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
received:
31
03
2022
accepted:
10
05
2022
pubmed:
16
6
2022
medline:
13
8
2022
entrez:
15
6
2022
Statut:
ppublish
Résumé
Although the role of Lipocalin-2 (LCN2) in cancer development has been focused on recent studies, the molecular mechanisms and clinical relevance of LCN2 in gastric cancer (GC) still remain unclear. Transcriptome analysis of GC samples from public human data was performed according to Lauren's classification and molecular classification. In vitro, Western blotting, RT-PCR, wound healing assay and invasion assay were performed to reveal the function and mechanisms of LCN2 in cell proliferation, migration and invasion using LCN2 knockdown cells. Gene set enrichment analysis (GSEA) of GC samples from public human data was analyzed according to LCN2 expression. The clinical significance of LCN2 expression was investigated in GC patients from public data and our hospital. LCN2 was downregulated in diffuse-type GC, as well as in Epithelial-Mesenchymal Transition (EMT) type GC. LCN2 downregulation significantly promoted proliferation, invasion and migration of GC cells. The molecular mechanisms of LCN2 downregulation contribute to Matrix Metalloproteinases-2 (MMP2) stimulation which enhances EMT signaling in GC cells. GSEA revealed that LCN2 downregulation in human samples was involved in EMT signaling. Low LCN2 protein and mRNA levels were significantly associated with poor prognosis in patients with GC. LCN2 mRNA level was an independent prognostic factor for overall survival in GC patients. LCN2 has a critical role in EMT signaling via MMP2 activity during GC progression. Thus, LCN2 might be a promising therapeutic target to revert EMT signaling in GC patients with poor outcomes.
Sections du résumé
BACKGROUND
Although the role of Lipocalin-2 (LCN2) in cancer development has been focused on recent studies, the molecular mechanisms and clinical relevance of LCN2 in gastric cancer (GC) still remain unclear.
METHODS
Transcriptome analysis of GC samples from public human data was performed according to Lauren's classification and molecular classification. In vitro, Western blotting, RT-PCR, wound healing assay and invasion assay were performed to reveal the function and mechanisms of LCN2 in cell proliferation, migration and invasion using LCN2 knockdown cells. Gene set enrichment analysis (GSEA) of GC samples from public human data was analyzed according to LCN2 expression. The clinical significance of LCN2 expression was investigated in GC patients from public data and our hospital.
RESULTS
LCN2 was downregulated in diffuse-type GC, as well as in Epithelial-Mesenchymal Transition (EMT) type GC. LCN2 downregulation significantly promoted proliferation, invasion and migration of GC cells. The molecular mechanisms of LCN2 downregulation contribute to Matrix Metalloproteinases-2 (MMP2) stimulation which enhances EMT signaling in GC cells. GSEA revealed that LCN2 downregulation in human samples was involved in EMT signaling. Low LCN2 protein and mRNA levels were significantly associated with poor prognosis in patients with GC. LCN2 mRNA level was an independent prognostic factor for overall survival in GC patients.
CONCLUSIONS
LCN2 has a critical role in EMT signaling via MMP2 activity during GC progression. Thus, LCN2 might be a promising therapeutic target to revert EMT signaling in GC patients with poor outcomes.
Identifiants
pubmed: 35705840
doi: 10.1007/s10120-022-01305-w
pii: 10.1007/s10120-022-01305-w
pmc: PMC9365736
doi:
Substances chimiques
LCN2 protein, human
0
Lipocalin-2
0
RNA, Messenger
0
MMP2 protein, human
EC 3.4.24.24
Matrix Metalloproteinase 2
EC 3.4.24.24
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
850-861Informations de copyright
© 2022. The Author(s).
Références
Reproduction. 2013 Dec 20;147(2):179-87
pubmed: 24194573
Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3913-8
pubmed: 19237579
Genome Biol. 2014;15(12):550
pubmed: 25516281
Int J Cancer. 2007 Jun 1;120(11):2426-34
pubmed: 17294443
Gastric Cancer. 2020 May;23(3):473-482
pubmed: 31773340
Cancer Sci. 2017 Nov;108(11):2176-2186
pubmed: 28859238
Annu Rev Nutr. 2017 Aug 21;37:103-130
pubmed: 28628361
Lancet. 2020 Aug 29;396(10251):635-648
pubmed: 32861308
Carcinogenesis. 2021 Feb 25;42(2):180-189
pubmed: 33284950
Mol Cancer. 2016 Dec 3;15(1):77
pubmed: 27912767
Nat Commun. 2018 May 3;9(1):1777
pubmed: 29725014
Nat Med. 2015 May;21(5):449-56
pubmed: 25894828
PLoS One. 2019 Nov 8;14(11):e0224727
pubmed: 31703077
Hepatology. 2013 Oct;58(4):1349-61
pubmed: 23696034
Nat Biotechnol. 2019 Aug;37(8):907-915
pubmed: 31375807
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Tumour Biol. 2015 Sep;36(9):6883-9
pubmed: 25851348
Gastric Cancer. 2016 Apr;19(2):431-442
pubmed: 26100130
Br J Cancer. 2010 Mar 2;102(5):898-907
pubmed: 20145613
Sci Rep. 2016 Oct 26;6:36138
pubmed: 27782193
Cell Commun Signal. 2019 Sep 10;17(1):118
pubmed: 31500632
F1000Res. 2015 Dec 30;4:1521
pubmed: 26925227
Lancet Oncol. 2013 Nov;14(12):e535-47
pubmed: 24176572
Int J Mol Sci. 2021 Dec 05;22(23):
pubmed: 34884961
Oncogene. 2015 Feb 12;34(7):878-89
pubmed: 24608426
Oncol Rep. 2015 Oct;34(4):2179-87
pubmed: 26259977
Nat Methods. 2017 Apr;14(4):417-419
pubmed: 28263959
Am J Transl Res. 2015 Nov 15;7(11):2141-58
pubmed: 26807164
Brief Bioinform. 2013 Mar;14(2):178-92
pubmed: 22517427
Nat Rev Clin Oncol. 2016 Jun;13(6):348-60
pubmed: 26925958
Br J Cancer. 2018 Mar 20;118(6):867-877
pubmed: 29438363